Merck & Co./$MRK
1D1W1MYTD1Y5YMAX
Capital at risk
About Merck & Co.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. In cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 53% of the company's 2025 sales were generated from US human health (pharmaceuticals and vaccines).
- Ticker
- $MRK
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 74,000
- Headquarters
- Rahway, United States
- Website
- www.merck.com
Merck & Co. Metrics
BasicAdvanced
$371B
118.11
$1.27
0.21
$3.36
2.26%
Price and volume
Market cap
$371B
Beta
0.21
52-week high
$156.92
52-week low
$77.58
Average daily volume
10M
Dividend rate
$3.36
Financial strength
Current ratio
1.323
Quick ratio
0.742
Long term debt to equity
121.68
Total debt to equity
106.936
Dividend payout ratio (TTM)
261.52%
Interest coverage (TTM)
7.26%
Profitability
EBITDA (TTM)
28,871
Gross margin (TTM)
75.90%
Net profit margin (TTM)
4.77%
Operating margin (TTM)
35.28%
Effective tax rate (TTM)
46.72%
Revenue per employee (TTM)
$900,000
Management effectiveness
Return on assets (TTM)
11.87%
Return on equity (TTM)
6.96%
Valuation
Price to earnings (TTM)
118.106
Price to revenue (TTM)
5.593
Price to book
8.09
Price to tangible book (TTM)
-80.21
Price to free cash flow (TTM)
23.205
Free cash flow yield (TTM)
4.31%
Free cash flow per share (TTM)
6.478
Dividend yield (TTM)
2.24%
Forward dividend yield
2.26%
Growth
Revenue change (TTM)
4.64%
Earnings per share change (TTM)
-80.37%
3-year revenue growth (CAGR)
4.51%
10-year revenue growth (CAGR)
5.37%
3-year earnings per share growth (CAGR)
1.25%
10-year earnings per share growth (CAGR)
-3.53%
3-year dividend per share growth (CAGR)
5.34%
10-year dividend per share growth (CAGR)
6.20%
What the Analysts think about Merck & Co.
Analyst ratings (Buy, Hold, Sell) for Merck & Co. stock.
Analyst projections of the future price of Merck & Co. stock.
Bulls say / Bears say
Merck reported Q2 2026 revenue of $16.61 billion, up 5% year-over-year, driven by Keytruda sales of $8.37 billion (+5%) and raised its full-year revenue forecast, underscoring robust demand for its immuno-oncology franchise. (Reuters)
Merck said it would acquire Terns Pharmaceuticals for up to $6.7 billion in March 2026, adding late-stage hematology candidate TERN-701 to its pipeline and diversifying growth prospects ahead of Keytruda's looming patent loss. (Reuters)
Gilead and Merck announced that their investigational once-weekly HIV pill maintained viral suppression in two Phase III trials, supporting regulatory filings and expanding Merck’s pipeline beyond oncology. (Reuters)
Keytruda is scheduled to lose key U.S. patent protections beginning in 2028, exposing its ~$30 billion franchise to biosimilar competition and threatening a significant revenue stream. (Reuters)
Merck cut its 2026 adjusted EPS guidance to $2.66–$2.76 from $5.04–$5.16 to reflect $5.7 billion of acquisition charges, highlighting margin pressure from its recent deals. (Reuters)
Merck posted a Q1 2026 adjusted loss of $1.28 per share, including a $3.62 per share charge for the acquisition of Cidara Therapeutics, underscoring acquisition-related financial risks. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 19 Aug 2026.
Merck & Co. Financial Performance
Revenues and expenses
Merck & Co. Earnings Performance
Company profitability
Upcoming events
Merck & Co. News
AllArticlesVideos
Funds containing Merck & Co.
AllEURGBPUSD
Fund name | Fund size | $MRK weighting |
|---|---|---|
iShares S&P 500 Health Care Sector€IUHE | €125M | 5.39% |
iShares MSCI World Health Care Sector Advanced€CBUF | €606M | 3.39% |
iShares MSCI USA Quality Dividend ESG£HDIQ | £579M | 2.70% |
iShares MSCI World Quality Dividend$WQDV | $1.8B | 2.54% |
iShares MSCI World Quality Dividend£WQDS | £1.3B | 2.54% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.